Comparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitus

Basit Öğe Kaydı
dc.authoridkeskin, lezan/0000-0001-8283-4516
dc.authorwosidkeskin, lezan/HJP-0902-2023
dc.contributor.authorKeskin, L.
dc.contributor.authorYaprak, B.
dc.date.accessioned2024-08-04T20:57:29Z
dc.date.available2024-08-04T20:57:29Z
dc.date.issued2022
dc.departmentİnönü Üniversitesien_US
dc.description.abstractOBJECTIVE: Obesity and Type 2 diabetes mellitus are growing health problems all over the world. The aim of this study is the comparison of 3 mg liraglutide and metformin combination, metformin monotherapy on the blood glucose regulation, weight loss and lipid panel in the patients with Type 2 diabetes melli-tus whose BMI is >= 30 kg/m(2). PATIENTS AND METHODS: 276 patients in-cluded in the study were divided into two groups (1:1); liraglutide (3 mg) + metformin combination (L+M) and metformin monotherapy (M) (2x1,000 mg) (exercise and diet were regulated in both groups). Patients' body composition measure-ments were performed and fasting blood glu-cose, postprandial blood glucose, HbA1c, tri-glyceride, total cholesterol, LDL, HDL levels were measured by TANITA device prior to the therapy and in the week 12 of the therapy. RESULTS: The average age of 276 patients included in the study was 49.70 +/- 7.93 years. A statistically significant decrease was noted in weight, BMI, fasting blood glucose, postprandi-al blood glucose, HbA1c values of both groups at the end of the third month. 11.3 kg of weight was lost on average in L+M group (-12.3%); 4.5 kg of weight was lost in the monotherapy group (-4.9%). A decrease of 14.3% was seen in the body fat mass, 2.1% in the muscle mass in L+M group and a decrease of 4.4% in the body fat mass and 6.1% in the muscle mass in the mono -therapy group. The decrease in the body fat was higher at a statistically significant level in L+M group and the decrease in the muscle mass was higher in the monotherapy group. HbA1c de-creased by 17.9% in L+M group (-1.49 +/- 0.46, Co-hen's d=2.68), 5.3% in the monotherapy group (-0.37 +/- 0.26, Cohen's d=0.90). The decrease in TG, total cholesterol, LDL was higher at a sta-tistically significant level in L+M group. The increase in HDL level was higher in the mono -therapy group (L+M=22.7%, M=35.4%). A weight loss that was over 10% occurred in 4.3% of the patients in the monotherapy group and 68.1% of the combined therapy group at the end of 12 weeks (95% C.I. OR=19.49-121.65). CONCLUSIONS: The effect of the combination of liraglutide 3 mg and metformin on blood glu-cose regulation, weight loss (fat loss, muscle conservation) was found to be superior to the metformin monotherapy in the obese patients with Type 2 diabetes mellitus according to the early period results.en_US
dc.identifier.endpage6820en_US
dc.identifier.issn1128-3602
dc.identifier.issue18en_US
dc.identifier.pmid36196729en_US
dc.identifier.startpage6813en_US
dc.identifier.urihttps://hdl.handle.net/11616/102672
dc.identifier.volume26en_US
dc.identifier.wosWOS:000876873600010en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherVerduci Publisheren_US
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetesen_US
dc.subjectObesityen_US
dc.subjectMetforminen_US
dc.subjectLiraglutideen_US
dc.titleComparison of the effect of liraglutide and metformin therapy on the disease regulation and weight loss in obese patients with Type 2 diabetes mellitusen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu